Modality
Small Molecule
MOA
SOS1i
Target
EZH2
Pathway
Incretin
Urothelial Ca
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Sep 2030
Phase 1Current
NCT04282044
1,216 pts·Urothelial Ca
2020-02→2025-04·Recruiting
NCT03898549
95 pts·Urothelial Ca
2023-11→2030-09·Not yet recruiting
1,311 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-0712mo agoPh2 Data· Urothelial Ca
2030-09-144.5y awayPh2 Data· Urothelial Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2025-04-07 · 12mo ago
Urothelial Ca
Ph2 Data
2030-09-14 · 4.5y away
Urothelial Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04282044 | Phase 1/2 | Urothelial Ca | Recruiting | 1216 | eGFR |
| NCT03898549 | Phase 1/2 | Urothelial Ca | Not yet recr... | 95 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |